(22 May 2025)
RESTRICTION SUMMARY:
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark – 26 September 2023
1. Close of diabetes drug Ozempic in packaging line
2. Wide of diabetes drug Ozempic in packaging line
ASSOCIATED PRESS
New York – 20 May 2025
3. SOUNDBITE (English) Lucas Mavromatis, New York University:
"So the question we’re investigating in this study is whether the use of GLP-1 receptor agonists, which is a medication for weight loss and diabetes, is associated with a lower risk of obesity-associated cancers as compared to DPP-4 inhibitors, another medication for diabetes."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark – 26 September 2023
4. Various of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
Houston – 20 May 2025
5. SOUNDBITE (English) Dr. Ernest Hawk, MD Anderson Cancer Center:
"Well, GLP-1 agonists are a relatively new treatment for diabetes. And there’s been a lot of discussion that they’re very effective in weight management as well. Been approved for both of those indications by the FDA. And so there’s a lot of interest in whether their actions in reducing obesity and controlling diabetes might also affect one of the long term outcomes of those conditions and that is the development of cancer."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark – 26 September 2023
6. Various of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
Houston – 20 May 2025
7. SOUNDBITE (English) Dr. Ernest Hawk, MD Anderson Cancer Center:
"Ozempic is probably one of the best known for diabetes, and Wegovy would be another example."
ASSOCIATED PRESS
ARCHIVE: Temecula, California – 30 April 2024
8. STILL: Wegovy injectable pens
ASSOCIATED PRESS
New York – 20 May 2025
9. SOUNDBITE (English) Lucas Mavromatis, New York University:
"So we found that people who take GLP-1 receptor agonists in our cohort of American patients have a lower incidence of obesity related cancers compared to those who take DPP-4 inhibitors."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark – 26 September 2023
10. Shot of box of diabetes drug Ozempic at Novo Nordisk production facility
ASSOCIATED PRESS
Houston – 20 May 2025
11. SOUNDBITE (English) Dr. Ernest Hawk, MD Anderson Cancer Center:
"It is an observational study and therefore we can’t really make inferences about causation. That is we don’t know that the use of these drugs resulted in that reduction of obesity related cancers."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark – 26 September 2023
12. Shot of box of diabetes drug Ozempic at Novo Nordisk production facility
ASSOCIATED PRESS
Houston – 20 May 2025
13. SOUNDBITE (English) Dr. Ernest Hawk, MD Anderson Cancer Center:
"Yeah, they reported a reduction in obesity-related cancers, about 7 or 8%, as well as a reduction in overall mortality of about the same magnitude, 7 or 8%."
ASSOCIATED PRESS
ARCHIVE: St. Petersburg, Florida – 7 November 2023
14. Kelly Burns, tirzepatide clinical trial participant, cooks behind an injectable pen of tirzepatide
ASSOCIATED PRESS
New York – 20 May 2025
15. SOUNDBITE (English) Lucas Mavromatis, New York University:
"So ultimately we were comparing 85,015 GLP-1 users versus 85, 015 DPP-4 users."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark – 26 September 2023
16. Wide of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
New York – 20 May 2025
17. SOUNDBITE (English) Lucas Mavromatis, New York University:
ASSOCIATED PRESS
Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Twitter: https://twitter.com/AP_Archive
Facebook: https://www.facebook.com/APArchives
Instagram: https://www.instagram.com/APNews/
You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/dbbf7c6945c54ccc8cbbd6b345e6f13c
Author: AP Archive
Go to Source
News post in May 27, 2025, 9:05 pm.
Visit Our Sponsor’s:
News Post In – News
